Martinez, Eliana C.
Li, Jinliang
Ataam, Jennifer Arthur
Tokarski, Kristin
Thakur, Hrishikesh
Karakikes, Ioannis
Dodge-Kafka, Kimberly
Kapiloff, Michael S. http://orcid.org/0000-0002-7005-6953
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL126825, R01HL146111, R01HL153835, R01HL126825, R01HL153835, R01HL146111)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Article History
Received: 13 September 2021
Revised: 19 January 2022
Accepted: 20 January 2022
First Online: 1 February 2022
Ethical approval
: Animal research was approved by the Institutional Animal Care and Use Committee at the University of Miami and the University of Connecticut. The Stanford University Institutional Review Board approved the use of pluripotent stem cells.
: Drs. Kapiloff and Li are inventors of patent-protected intellectual property concerning the targeting of mAKAPĪ² signalosomes to treat heart failure, by which they, the University of Miami, and Stanford University may gain royalties from future commercialization. Dr. Kapiloff holds equity in Anchored RSK3 Inhibitors, LLC, and Cardiac RSK3 Inhibitors, LLC, companies interested in developing mAKAP signalosome-targeted therapies.